International Clinical Trial: Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07460206) titled 'Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Condition: ccRCC

Intervention: Drug: Pembrolizumab 200 mg Q3W

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2026

Target Sample Size: 108

To know more, visit https://clinicaltrials.gov/study/NCT07460206

Published by HT Digital Content S...